Advanced

Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism

Gottsäter, Anders LU (2017) In Bailliere's Best Practice and Research in Clinical Gastroenterology 31(1). p.105-109
Abstract

Visceral arteries such as the coeliac (CA), superior mesenteric (SMA), and the inferior mesenteric artery (IMA) might be affected by atherosclerotic occlusive lesions with or without thrombosis or embolization causing ischaemic symptoms from the gastrointestinal tract.After treatment of an acute event, these patients should be offered both non-pharmacological and pharmacological secondary prevention to reduce risk for future ischaemic arterial manifestations. Patients with mesenteric ischaemia caused by atherosclerosis should be evaluated concerning platelet antiaggregation with low dose aspirin or clopidogrel, and those with cardioembolic disease should be recommended anticoagulant treatment with either warfarin or one of the direct... (More)

Visceral arteries such as the coeliac (CA), superior mesenteric (SMA), and the inferior mesenteric artery (IMA) might be affected by atherosclerotic occlusive lesions with or without thrombosis or embolization causing ischaemic symptoms from the gastrointestinal tract.After treatment of an acute event, these patients should be offered both non-pharmacological and pharmacological secondary prevention to reduce risk for future ischaemic arterial manifestations. Patients with mesenteric ischaemia caused by atherosclerosis should be evaluated concerning platelet antiaggregation with low dose aspirin or clopidogrel, and those with cardioembolic disease should be recommended anticoagulant treatment with either warfarin or one of the direct oral anticoagulants (DOAC; apixaban, dabigatran, edoxaban, or rivaroxaban). In all patients, blood pressure should be lowered to <140/90 mmHg with ACE-inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, or thiazide diuretics, and LDL-cholesterol should be kept at <1.8 mmol/l, preferably with statins. If present, diabetes should be treated aiming at good metabolic control, and all smokers should be recommended cessation.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Anticoagulation, Antiplatelet treatment, Atherosclerosis, Blood pressure lowering, Coeliac artery (CA), Embolization, Inferior mesenteric artery (IMA), Lipid lowering, Superior mesenteric artery (SMA), Thrombosis
in
Bailliere's Best Practice and Research in Clinical Gastroenterology
volume
31
issue
1
pages
105 - 109
publisher
Baillière Tindall
external identifiers
  • scopus:84999737840
ISSN
1521-6918
DOI
10.1016/j.bpg.2016.07.004
language
English
LU publication?
no
id
4fd01e27-edfe-4589-b9b7-8ecd1c9d3ee1
date added to LUP
2016-12-30 13:07:24
date last changed
2018-01-07 11:43:33
@article{4fd01e27-edfe-4589-b9b7-8ecd1c9d3ee1,
  abstract     = {<p>Visceral arteries such as the coeliac (CA), superior mesenteric (SMA), and the inferior mesenteric artery (IMA) might be affected by atherosclerotic occlusive lesions with or without thrombosis or embolization causing ischaemic symptoms from the gastrointestinal tract.After treatment of an acute event, these patients should be offered both non-pharmacological and pharmacological secondary prevention to reduce risk for future ischaemic arterial manifestations. Patients with mesenteric ischaemia caused by atherosclerosis should be evaluated concerning platelet antiaggregation with low dose aspirin or clopidogrel, and those with cardioembolic disease should be recommended anticoagulant treatment with either warfarin or one of the direct oral anticoagulants (DOAC; apixaban, dabigatran, edoxaban, or rivaroxaban). In all patients, blood pressure should be lowered to &lt;140/90 mmHg with ACE-inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, or thiazide diuretics, and LDL-cholesterol should be kept at &lt;1.8 mmol/l, preferably with statins. If present, diabetes should be treated aiming at good metabolic control, and all smokers should be recommended cessation.</p>},
  author       = {Gottsäter, Anders},
  issn         = {1521-6918},
  keyword      = {Anticoagulation,Antiplatelet treatment,Atherosclerosis,Blood pressure lowering,Coeliac artery (CA),Embolization,Inferior mesenteric artery (IMA),Lipid lowering,Superior mesenteric artery (SMA),Thrombosis},
  language     = {eng},
  number       = {1},
  pages        = {105--109},
  publisher    = {Baillière Tindall},
  series       = {Bailliere's Best Practice and Research in Clinical Gastroenterology},
  title        = {Pharmacological secondary prevention in patients with mesenterial artery atherosclerosis and arterial embolism},
  url          = {http://dx.doi.org/10.1016/j.bpg.2016.07.004},
  volume       = {31},
  year         = {2017},
}